Fragile X syndrome (MIM number 30955) is among the most common human single gene disorders, and is the leading cause of inherited mental retardation, with an estimated frequency of 1/2000-1/4000 individuals world-wide. The gene defective in fragile X syndrome (FMR1) was identified by positional cloning in 1991, yet its function, and the consequences of its absence remain unknown. The FMR1 protein interacts with mRNAs in a variety of cell types, and has been shown to associate with ribosomes. These apparently fundamental properties are difficult to reconcile with the relatively mild phenotype found in fragile X patients and in a mouse knockout of the Fmr1 gene. The central hypothesis of the project proposed here is that two FMR1-related proteins, FXR1 and FXR2 provide redundancy of function for FMR1. This redundancy masks the phenotypic consequences of loss of function mutations in humans and mice that would allow better definition of the function of FMR1. In order to test this hypothesis, mutations in the Fxr1 and Fxr2 genes are proposed. These will be introduced into the mouse genome with the capability to provide conditional knockouts using the site specific recombinase Cre derived from phage P1, which recognizes lox P sites for recombination. Mutant mice will be analyzed by biochemical, histological and behavioral methods in order to determine the consequences of the absence of one or more of these genes. Conditional mutations will be created to investigate tissue specific or developmental timing effects of gene ablation. Mutations in the Fxr1 and Fxr2 proteins, especially in combination with Fmr1 mutations, should provide resolution of the redundancy question. Such mutations and combinations of mutations will also provide important evidence for the functions of these genes. Results from this project will provide additional data regarding the normal function of FMR1 and the consequences of its absence in fragile X syndrome. These data will allow further investigation of potential therapeutic intervention in this common form of mental retardation.
| Levenga, Josien; Hayashi, Shigemi; de Vrij, Femke M S et al. (2011) AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol Dis 42:311-7 |
| Whitman, Samantha A; Cover, Cathleen; Yu, Lily et al. (2011) Desmoplakin and talin2 are novel mRNA targets of fragile X-related protein-1 in cardiac muscle. Circ Res 109:262-71 |
| Guo, Weixiang; Allan, Andrea M; Zong, Ruiting et al. (2011) Ablation of Fmrp in adult neural stem cells disrupts hippocampus-dependent learning. Nat Med 17:559-65 |
| Willemsen, R; Levenga, J; Oostra, B A (2011) CGG repeat in the FMR1 gene: size matters. Clin Genet 80:214-25 |
| Levenga, Josien; de Vrij, Femke M S; Oostra, Ben A et al. (2010) Potential therapeutic interventions for fragile X syndrome. Trends Mol Med 16:516-27 |
| Levenga, Josien; Buijsen, Ronald A M; Rifé, Maria et al. (2009) Ultrastructural analysis of the functional domains in FMRP using primary hippocampal mouse neurons. Neurobiol Dis 35:241-50 |
| Galloway, Jocelyn N; Nelson, David L (2009) Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome. Future Neurol 4:785 |
| Brouwer, J R; Willemsen, R; Oostra, B A (2009) The FMR1 gene and fragile X-associated tremor/ataxia syndrome. Am J Med Genet B Neuropsychiatr Genet 150B:782-98 |
| Oostra, Ben A; Willemsen, Rob (2009) FMR1: a gene with three faces. Biochim Biophys Acta 1790:467-77 |
| Brouwer, Judith R; Willemsen, Rob; Oostra, Ben A (2009) Microsatellite repeat instability and neurological disease. Bioessays 31:71-83 |
Showing the most recent 10 out of 48 publications
